• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重新思考癌症临床试验在 COVID-19 及以后的应用。

Rethinking cancer clinical trials for COVID-19 and beyond.

机构信息

Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.

University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.

出版信息

Nat Cancer. 2020 Jun;1(6):568-572. doi: 10.1038/s43018-020-0083-x.

DOI:10.1038/s43018-020-0083-x
PMID:35121973
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7258610/
Abstract

The risks posed to patients with cancer by the current COVID-19 pandemic demand rapid structural changes in healthcare delivery, with many positive changes likely to continue long term. An immediate critical reassessment of trial methodology based on clinical and scientific priorities is essential to ensure the resilience of clinical cancer research and optimize patient-centered care.

摘要

当前 COVID-19 大流行给癌症患者带来的风险要求医疗服务迅速进行结构性改革,其中许多积极的变化可能会长期持续。基于临床和科学优先事项,对试验方法进行紧急批判性重新评估对于确保临床癌症研究的弹性和优化以患者为中心的护理至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aedc/7258610/c91c816bbeeb/43018_2020_83_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aedc/7258610/a5bf24adfb15/43018_2020_83_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aedc/7258610/c91c816bbeeb/43018_2020_83_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aedc/7258610/a5bf24adfb15/43018_2020_83_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aedc/7258610/c91c816bbeeb/43018_2020_83_Fig2_HTML.jpg

相似文献

1
Rethinking cancer clinical trials for COVID-19 and beyond.重新思考癌症临床试验在 COVID-19 及以后的应用。
Nat Cancer. 2020 Jun;1(6):568-572. doi: 10.1038/s43018-020-0083-x.
2
Impact of COVID-19 Outbreak through Telemedicine Implementation on Data Reporting During Oncology Clinical Trials.COVID-19 疫情期间通过实施远程医疗对肿瘤临床试验数据报告的影响。
Cancer Invest. 2021 Jan;39(1):15-20. doi: 10.1080/07357907.2020.1858311. Epub 2020 Dec 10.
3
The impact of the COVID-19 pandemic on cancer care.新冠疫情对癌症护理的影响。
Nat Cancer. 2020 Jun;1(6):565-567. doi: 10.1038/s43018-020-0074-y.
4
World Cancer Day 2021: A recognition of the COVID-19 heroes supporting and caring for cancer patients around the world.2021年世界癌症日:致敬全球支持和关爱癌症患者的抗疫英雄。
Int J Cancer. 2021 Jul 1;149(1):8-9. doi: 10.1002/ijc.33480. Epub 2021 Jan 25.
5
Challenges of Cancer Immunotherapy during the COVID-19 Pandemic.新冠疫情期间癌症免疫疗法面临的挑战
Cancer Invest. 2021 Feb;39(2):115-119. doi: 10.1080/07357907.2020.1864129. Epub 2020 Dec 27.
6
Optimizing the Use of Telemedicine in Oncology Care: Postpandemic Opportunities.优化肿瘤学医疗中的远程医疗使用:后疫情时代的机遇。
Clin Cancer Res. 2021 Feb 15;27(4):933-936. doi: 10.1158/1078-0432.CCR-20-3758. Epub 2020 Nov 23.
7
Clinical trials and Haemophilia during the COVID-19 pandemic: Madrid's experience.COVID-19大流行期间的临床试验与血友病:马德里的经验
Haemophilia. 2020 Sep;26(5):e247-e249. doi: 10.1111/hae.14055. Epub 2020 Jun 12.
8
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.《2021年临床癌症进展:美国临床肿瘤学会抗癌进展报告》
J Clin Oncol. 2021 Apr 1;39(10):1165-1184. doi: 10.1200/JCO.20.03420. Epub 2021 Feb 2.
9
The Day After COVID-19-Time to Rethink Oncology Clinical Research.新冠疫情后的肿瘤学临床研究:是时候重新思考了。
JAMA Oncol. 2021 Jan 1;7(1):23-24. doi: 10.1001/jamaoncol.2020.4240.
10
AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care.美国癌症研究协会关于新冠病毒病对癌症研究和患者护理影响的报告。
Clin Cancer Res. 2022 Feb 15;28(4):609-610. doi: 10.1158/1078-0432.CCR-22-0192.

引用本文的文献

1
Underinvested, Under-Referred, and Underserved: Applying a Gender Equity Continuum Framework in Cancer Control Continuum Programs and Policies to Expand to Transgender and Nonbinary Populations.投资不足、转诊不足和服务不足:在癌症控制连续项目和政策中应用性别平等连续统一体框架,以扩大至跨性别和非二元性别群体。
JCO Oncol Adv. 2025 May 7;2(1):e2400023. doi: 10.1200/OA.24.00023. eCollection 2025.
2
Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center.在一家三级癌症中心的新型冠状病毒肺炎大流行期间,实体恶性肿瘤临床研究的患者招募情况。
Neoplasia. 2023 Oct 27;46:100946. doi: 10.1016/j.neo.2023.100946.
3

本文引用的文献

1
Caring for patients with cancer in the COVID-19 era.在 COVID-19 时代照顾癌症患者。
Nat Med. 2020 May;26(5):665-671. doi: 10.1038/s41591-020-0874-8. Epub 2020 Apr 16.
2
COVID-19 Emergency and the Need to Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice.COVID-19疫情与癌症临床实践中加速采用电子患者报告结局的必要性。
JCO Oncol Pract. 2020 Jun;16(6):295-298. doi: 10.1200/OP.20.00237. Epub 2020 May 1.
3
COVID-19 transforms health care through telemedicine: Evidence from the field.
Recommendations to promote equity, diversity and inclusion in decentralized clinical trials.
促进去中心化临床试验中公平、多样性和包容性的建议。
Nat Med. 2024 Nov;30(11):3075-3084. doi: 10.1038/s41591-024-03323-w. Epub 2024 Oct 29.
4
What Is Ailing Oncology Clinical Trials? Can We Fix Them?肿瘤临床研究的症结在哪里?我们能解决吗?
Curr Oncol. 2024 Jun 28;31(7):3738-3751. doi: 10.3390/curroncol31070275.
5
TBCRC 057: Survey about willingness to participate in cancer clinical trials during the pandemic.TBCRC 057:关于疫情期间参与癌症临床试验意愿的调查。
Cancer Med. 2024 Mar;13(5):e7090. doi: 10.1002/cam4.7090.
6
Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials.研究者在癌症治疗试验中对远程医疗和远程患者监测的体验和舒适度。
Oncologist. 2024 Apr 4;29(4):356-363. doi: 10.1093/oncolo/oyad237.
7
Telehealth utilization in gynecologic oncology clinical trials.远程医疗在妇科肿瘤临床试验中的应用。
Gynecol Oncol. 2023 Oct;177:103-108. doi: 10.1016/j.ygyno.2023.08.011. Epub 2023 Aug 31.
8
Eighteen Years of Medical Oncology in Morocco: A Bibliometric Evaluation.摩洛哥肿瘤内科学18年:文献计量学评估
Cureus. 2023 May 9;15(5):e38766. doi: 10.7759/cureus.38766. eCollection 2023 May.
9
Shifting behavioral intervention research to virtual methods: Challenges and solutions in practice, during and after the COVID-19 pandemic.将行为干预研究转向虚拟方法:COVID-19大流行期间及之后实践中的挑战与解决方案
J Telemed Telecare. 2025 Jan;31(1):134-139. doi: 10.1177/1357633X231167899. Epub 2023 Apr 26.
10
Digital health technologies and Alzheimer's disease clinical trials: might decentralized clinical trials increase participation by people with cognitive impairment?数字健康技术与阿尔茨海默病临床试验:去中心化临床试验是否会增加认知障碍患者的参与度?
Alzheimers Res Ther. 2023 Apr 27;15(1):87. doi: 10.1186/s13195-023-01227-4.
COVID-19 通过远程医疗改变医疗保健:来自现场的证据。
J Am Med Inform Assoc. 2020 Jul 1;27(7):1132-1135. doi: 10.1093/jamia/ocaa072.
4
Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic.国家监管机构关于在新冠疫情期间正在进行的癌症试验的建议。
Lancet Oncol. 2020 May;21(5):624-627. doi: 10.1016/S1470-2045(20)30226-6. Epub 2020 Apr 8.
5
Detection of ctDNA from Dried Blood Spots after DNA Size Selection.经 DNA 大小选择后从干血斑中检测循环肿瘤 DNA。
Clin Chem. 2020 May 1;66(5):697-705. doi: 10.1093/clinchem/hvaa050.
6
Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.皮下注射曲妥珠单抗的安全性和耐受性,IIIb 期开放标签 BELIS 研究在 HER2 阳性早期乳腺癌中的结果。
Breast Cancer Res Treat. 2020 May;181(1):97-105. doi: 10.1007/s10549-020-05604-7. Epub 2020 Apr 2.
7
The Future of Wearable Technologies and Remote Monitoring in Health Care.可穿戴技术与远程监测在医疗保健领域的未来
Am Soc Clin Oncol Educ Book. 2019 Jan;39:115-121. doi: 10.1200/EDBK_238919. Epub 2019 May 17.
8
A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome.一种可穿戴远程监测系统,用于识别 QT 间期延长或有药物引起长 QT 综合征风险的受试者。
Int J Cardiol. 2018 Sep 1;266:89-94. doi: 10.1016/j.ijcard.2018.03.097.
9
Perspectives on Electronic Informed Consent From Patients Underrepresented in Research in the United States: A Focus Group Study.美国研究中代表性不足患者对电子知情同意的看法:一项焦点小组研究
J Empir Res Hum Res Ethics. 2018 Oct;13(4):338-348. doi: 10.1177/1556264618773883. Epub 2018 May 23.
10
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.扩大入选标准以使临床试验更具代表性:美国临床肿瘤学会与癌症研究之友联合研究声明
J Clin Oncol. 2017 Nov 20;35(33):3737-3744. doi: 10.1200/JCO.2017.73.7916. Epub 2017 Oct 2.